Abstract
Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis between COVID-19-induced pneumonia and immunotherapy-induced pneumonitis may be challenging in the era of COVID-19 outbreak. Some clinical symptoms and radiological findings of pneumonitis can be attributed to the coronavirus infection as well as to an immune-related adverse event. Identifying the exact cause of a pneumonitis in patients on treatment with immunotherapy is crucial to promptly start the most appropriate treatment. The proper management of immune checkpoint inhibitors for the risk of pneumonia must take into account a series of parameters. Accurate attention should be payed to symptoms like cough, fever and dyspnea during immunotherapy.
Original language | English |
---|---|
Article number | e000952 |
Journal | Journal for ImmunoTherapy of Cancer |
Volume | 8 |
Issue number | 2 |
DOIs | |
Publication status | Published - Jul 21 2020 |
Keywords
- CTLA-4 Antigen
- cytokines
- immunotherapy
- melanoma
- programmed cell death 1 receptor
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Molecular Medicine
- Oncology
- Pharmacology
- Cancer Research